HBK Sorce Advisory LLC Has $847,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

HBK Sorce Advisory LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 24.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 9,852 shares of the company’s stock after selling 3,230 shares during the period. HBK Sorce Advisory LLC’s holdings in Novo Nordisk A/S were worth $847,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth about $28,000. Center for Financial Planning Inc. boosted its holdings in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Dunhill Financial LLC grew its stake in Novo Nordisk A/S by 196.8% in the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after acquiring an additional 311 shares during the period. Albion Financial Group UT increased its holdings in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $46,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent research reports. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $75.76 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12-month low of $73.80 and a 12-month high of $148.15. The firm has a market cap of $339.98 billion, a price-to-earnings ratio of 23.03, a PEG ratio of 0.90 and a beta of 0.42. The company has a 50-day simple moving average of $84.15 and a two-hundred day simple moving average of $103.64.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.